Erasca, Inc. (ERAS)
13.37
-0.04
(-0.30%)
USD |
NASDAQ |
Jun 10, 16:00
13.38
0.00 (0.00%)
Pre-Market: 20:00
Erasca 1 Year Total Returns (Daily) : 730.4% for June 10, 2026
1 Year Total Returns (Daily) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical 1 Year Total Returns (Daily) Data
| Date | Value |
|---|---|
| June 10, 2026 | 730.4% |
| June 09, 2026 | 722.7% |
| June 08, 2026 | 704.4% |
| June 05, 2026 | 662.4% |
| June 04, 2026 | 767.3% |
| June 03, 2026 | 812.1% |
| June 02, 2026 | 846.0% |
| June 01, 2026 | 887.1% |
| May 29, 2026 | 785.5% |
| May 28, 2026 | 1.01K% |
| May 27, 2026 | 1.05K% |
| May 26, 2026 | 842.6% |
| May 22, 2026 | 828.9% |
| May 21, 2026 | 851.2% |
| May 20, 2026 | 768.8% |
| May 19, 2026 | 739.0% |
| May 18, 2026 | 699.2% |
| May 15, 2026 | 705.5% |
| May 14, 2026 | 716.5% |
| May 13, 2026 | 686.5% |
| May 12, 2026 | 646.8% |
| May 11, 2026 | 651.1% |
| May 08, 2026 | 628.1% |
| May 07, 2026 | 749.0% |
| May 06, 2026 | 772.0% |
| Date | Value |
|---|---|
| May 05, 2026 | 589.0% |
| May 04, 2026 | 541.8% |
| May 01, 2026 | 573.2% |
| April 30, 2026 | 629.5% |
| April 29, 2026 | 537.1% |
| April 28, 2026 | 607.1% |
| April 27, 2026 | 1.28K% |
| April 24, 2026 | 1.44K% |
| April 23, 2026 | 1.48K% |
| April 22, 2026 | 1.47K% |
| April 21, 2026 | 1.71K% |
| April 20, 2026 | 1.77K% |
| April 17, 2026 | 1.54K% |
| April 16, 2026 | 1.46K% |
| April 15, 2026 | 1.43K% |
| April 14, 2026 | 1.34K% |
| April 13, 2026 | 1.22K% |
| April 10, 2026 | 1.50K% |
| April 09, 2026 | 1.35K% |
| April 08, 2026 | 1.50K% |
| April 07, 2026 | 1.29K% |
| April 06, 2026 | 1.38K% |
| April 02, 2026 | 1.31K% |
| April 01, 2026 | 1.28K% |
| March 31, 2026 | 1.08K% |
Total Return Definition
The Total return is the change in price over a specific period of time that includes dividends and distributions paid.
1 Year Total Returns (Daily) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
1 Year Total Returns (Daily) Benchmarks
| Revolution Medicines, Inc. | 243.5% |
| Tango Therapeutics, Inc. | 541.6% |
| Kymera Therapeutics, Inc. | 60.97% |
| Bridgebio Oncology Therapeutics, Inc. | -- |
| ImmunityBio, Inc. | 109.0% |